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INTRODUCTION 
 Senile Macular Degeneration was first reported as a clinical entity 
In 1885 by Otto Haab. He  described a variety of pigmentary and atrophic 
changes in the macular region causing progressive impairment of central 
vision in patients more than 50 years 6. 
 Age Related Macular Degeneration is the leading cause of 
irreversible blindness in individuals over 50 years in developed 
countries.4 
DEFINITION 
 Age Related Maculopathy - is an exaggeration of the normal 
ageing  process characterized by discrete yellow spots at the macula 
(Drusen) or hyperpigmentation or depigmentation of the RPE associated 
with drusen 4 
 Age Related Macular Degeneration - is a more advanced ,sight 
threatening  stage of ARM characterized by one or more of the following  
 - Geographic atrophy of the RPE with visible underlying 
 choroidal vessels. 
 - Pigment epithelial detachment (PED) with or without 
 neurosensory detachment 
 
2
 - Subretinal or sub-RPE choroidal neovascularisation                                      
 - Fibroglial scar tissue,haemorrhage and exudates4 
 In the Framingham Eye study, an eye was considered to have 
AMD if pigment changes,Drusen,retinal changes associated with 
choroidal neovascularisation in individuals over 50 years of age were 
thought to be responsible for visual loss to 20/30 or worse , not as a result 
of cataract or other eye disease. 
 The definition of AMD should be expanded to include any 
eccentrically located atrophic or exudative process that would lower 
visual acuity if it spread into fixation, as well as excessive numbers or 
confluence of drusen 6 
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ANATOMY OF MACULA 
 Macula is an oval area at the posterior pole measuring about 5 mm 
in diameter.Its centre is located approximately 4 mm temporal and 0.8 
mm inferior to the centre of the optic disc. 
 Important clinical land marks within the macula are 
 1. Fovea 
 2. Foveola 
 3. Foveal Avascular Zone 
Fovea 
 This is a depression in the inner retinal surface at the centre of the 
macula.Its diameter is 1.5 mm.Ophthalmoscopically the fovea can be 
recognized by an oval light reflex arising from the increased thickness of  
the retina and internal limiting membrane in the parafoveal region.The 
parafoveal region is the thickest part of the retina containing 6-8 layers of 
ganglion cells. 
Foveola 
 This forms the central floor of the fovea and has a diameter of 0.35 
mm.It is thinnest part of the retina and is devoid of ganglion cells.Its 
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entire thickness consists only of cones and their nuclei and its subserves 
the most acute vision. 
 The umbo is a tiny depression in the very centre of the foveola 
which corresponds to the ophthalmoscopically visible foveolar reflex 
seen in most normal eyes. 
Foveal Avascular Zone 
 This measures 0.5 mm in diameter and is therefore situated inside 
the fovea but outside the foveola .The exact location of the foveal 
avascular zone can only be determined by FFA.It is a very important 
landmark I deciding whether or not to treat subretinal neovascular 
membranes at the macula by laser photo coagulation. 
Retinal Pigment Epithelium 
 This is a single layer of hexagonally shaped cells,the apices of 
which contain villous process which reach out towards the outer segment 
of the photoreceptors.The RPE cells in the fovea are taller (11.14 cms) 
and contains more and larger melanosomes. 
Bruchs membrane 
 This seperates the RPE from the choriocapillaries.On electron 
microscopy it consists of five elements: 
 
5
 1. Basal lamina of the RPE 
 2. Inner collagenous layer 
 3. Middle elastic layer 
 4. Outer collagenous layer 
 5. Basal lamina of the choriocapillaries 
 Changes in Bruchs membrane play an important part in AMD. 
Histology of macula 
 In the fovea and foveola there are no rod photoreceptors ,but only 
tightly packed cones. All other retinal elements except muller’s cells are 
largely absent. 
 Despite the displacement of bipolar and ganglion cells to the 
periphery of fovea, the cones and rods retain their vertical orientation but 
the inner and outer fibres of photoreceptors are inclined obliquely 
towards the periphery of macula. The horizontal course of inner 
photoreceptor fibres forms an external ‘Plexiform’ lamina-Henle’s layer 8 
 The annular zone external to the fovea centralis is divided into an 
inner parafoveal area and an outermost parafoveal area. 
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 The parafoveal region has greatest accumulation of bipolar cells 
and ganglion cells in the entire retina. 
 In the perifoveal area the density of cones decreases markedly and 
outer plexiform layer changes from Henle’s layer to a more usual 
arrangement. 
 The pigment epithelium and the adjoining chorio-capillary bed are 
increased over the macular region8 
 The external limiting membrane is pushed inward forming a 
depression which faces the choroid and has been called the fovea externa. 
Normal Aging 6 
 It is very relavant to discuss normal aging changes that take place 
at macula. 
 Aging is a natural biologic phenomenon, approximately 2-2.5 % of 
retinal cells may be lost per decade of life. There is no mitosis in these 
tissues to replace those lost. 
 - Loss of foveal and foveolar reflexes 
 - A few small hard drusen are almost always present 
 - Fine irregularity and increased tigroid nature of the fundus 
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- Choroidal vessels show clear cut edges and stand out under 
the macula 
 Histologically the pigment epithelium show pleomorphism 
involving size and shape (Friedman,1968).The most notable changes 
develop at the base of the cells, where there will be deposition of 
basement membrane material and shedding of membranous debris occur. 
An increase in lipofuscin content of the Retinal Pigment Epithelium and 
increase in height of the cell occur .The cone outer segment show 
increasing disorganization of their normally regular stacked discs dropout 
of foveal cones. This   is followed by an increase diameter of the inner 
segments of the cones. The outer segment of the rods become convoluted 
(Marshall et al ,1974) 
 Bruch’s membrane thickening is another constant change in aging. 
There is associated hyalinization, patchy basophilia (Kinningswoth, 
1987). The appearance of debris in Bruch’s membrane is due to the build 
up of lipofuscin in the retinal pigment epithelium. 
 Basal laminar deposits appear beneath the RPE. Membranous 
debris appear between strands of basal laminar deposits. It can also be 
traced through the basement membrane of RPE and the inner collagenous 
layer of Bruch’s membrane. This change as an important bearing on 
subsequent macular degeneration. 
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 In the choroid there is a loss of middle layer of medium sized 
vessels. The resulting thinning of the choroid throws the remaining larger 
vessels into greater prominence, accounting for the senile tigroid  fundus. 
Epidemiology 
 AMD is not only the leading cause of blindness in patients over 50 
years, it is now also the commonest overall cause of blindness in United 
states, Canada, England, Australia. 
 The National Eye Institute estimated that there may be more than 
16,000 new cases of legal blindness yearly from this disease. The 
incidence continues to rise as a result of the increasing percentage of 
elderly patients. The prevalence of AMD is age related. Framingham eye 
study estimated that in general population. 
 Between 52-64 years old incidence was 1.6%    
 Between 65-74 years old incidence was 6.4% 
 Between 75 and more years incidence was 30% 
 Women have higher prevalence rates than men (Liebowitz et al 
1980) 
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RISK FACTORS 
 Numerous risk factors have been incriminated suggesting that the 
disease is of multifactorial etiology. 
1. Age  
 The longer one survives, the higher the risk of acquiring the  
condition. It affects especially persons whose age exceeds the normal life 
expectancy. 
2. Sex 
 In the Framingham study females out numbered males but this also 
reflects the increased proportion of females in the older age group.  
3. Hereditary factors 
 Family history of loss of central vision is obtained in about 10-20% 
of affected individuals. 
4. Light ocular pigmentation 
 One hereditary factor influencing the disease is pigmentation. The 
incidence of AMD is higher in whites. Individuals with blue irides at 
risk.AMD is documented to be low in Blacks and Japanese. 
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5. Cigarette Smoking 
 An association appears to exist between AMD and cigarette 
smoking. 
6.  Hypertension 
 Conflicting results have appeared for the association between 
elevated systemic blood pressure and AMD. 
 But there is definite association with cardiovascular disease. 
7. Environmental Factors  
 AMD may be precipitated or exacerbated by cumulative damage 
from light toxicity if this exceeds the ability of molecular renewal to 
restore normal structure. Sunlight has long been suggested as a cause of 
AMD13 
8. Role of oxidants antioxidants 
 Studies from china have shown deficiency of serum zinc. Reports 
about serum copper levels is not equivocal. Deficiency of serum zinc 
seems to be a proved factor 10. 
  
 
11
9. Other host factors 
 Attention has to be given to claims of several studies relating AMD 
to elastotic degeneration of the dermis (Blumenkranz et al) decreased 
hand grip strength and hypermetropia. 
 Blumenkranz et al have stressed the association of elastotic  
degeneration in sun protected skin was predictive of exudative type of 
AMD10. 
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PATHOGENESIS OF ARMD 
 
 The RPE, Bruchs membrane and the choriocapillaries must       
function efficiently to serve as the nutritional complex for the  
photoreceptors .In a normal eye there are no deposits beneath the RPE.  
 Basement membrane is not unduly thickened and the choroid 
consists of the usual three layers of vessels. 
 In ARMD all these tissues are disturbed, each at one time been 
regarded as the tissue primarily at fault. 
OLD AGE-BRUCH MEMBRANE THICKENS 
atherosclerotic changes 
Inc.rigidity  &  dec compliance & increased post.cap resistance 
Inc hydrostatic pressure with lipid and protein exudation 
DRUSEN 
Degeneration of elastin & collagen 
Fragmentation of bruch memb 
Involutional changes in CC 
Inc VEGF 
ANGIOGENISIS 
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Most recent concepts10 
 Dr.Trempe suggests that they are due to degenerative changes 
occurring at the level of Bruchs membrane and the RPE and this 
commonly leads to atrophy. 
  Dr.Jalkh suggests  that one of the basic pathogenic factor in 
ARMD is a break in Bruchs membrane. All the changes that lead to 
severe visual loss due to ARMD occur after this break in Bruchs 
membrane.  
 The CNVM that originate from the choriocapillaries grow under 
the RPE and retina through this break in Bruchs membrane . The new 
vessels can be stimulated by factors related to inflammatory reaction 
involving lymphocytes, active inflammatory cells and tissue growth 
factors.                            
TYPES OF ARMD 
I . NON NEOVASCULAR / DRY ARMD 
 The hall mark of DRY ARMD is DRUSEN. Sequlae of DRY 
ARMD  are  
- Focal hyperpigmentation or atrophy of RPE 
- PED 
- Geographic atrophy  
 
14
II. NEOVASCULAR / WET ARMD 
The hall mark of WET ARMD is CNVM. Sequlae of WET ARMD 
are  
- Hemorrhagic PED 
- Vitreous hemorrhage 
- Subretinal disciform scarring  
- Massive exudation  
Exudative type of AMRD3 
This type of AMD is the major cause of severe visual loss in the 
elderly. Only 10% of AMD patients have the exudative form of the 
disease. In this group legal blindness is 88%. 
This exudative form is characterised by the presence of subretinal 
new vessel which leak serum, blood and lipids. Eventually, this exudative 
process leads to an organised scar tissue and the cicatric disciform lesion 
results in a significant and permanent loss of central vision.  
Drusen are viewed as anatomical markers of AMD. Focal 
hyperpigmentation of the RPE and confluent larger drusen were 
associated with significantly increased risk of exudative disease. 
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Smiddy and Fine report that 9.9% of patient with bilateral drusen 
developed exudative form of AMD over a 4 year follow up. 
The frequency of developing exudative maculopathy in the second 
eye ranges 12-43%. 
Using Kaplan Meier life table analysis Strahlman et al calculated a 
cumulative risk of 4% at 12 months, 10% at 24 months and 17% at 36 
months6. 
Clinical Presentation 
- Blurred vision 
- Distorted vision most often distorted NV 
- Decreased vision 
- Micropsia 
-  Metamorphopsia 
- Scotoma 
Symptoms arise from subretinal and intra retinal fluid and or blood.  
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 In most cases, the areas of distortion or scotoma can be mapped 
out on an Amsler Grid. 
Choroidal Neovascular Membranes (CNVM) 
 Clinically CNM appear as a grey green, round, oval irregular 
lesion. The grey green color might be due to RPE hyper plastic response 
to CNM. There may be subretinal lipids, haemorrhage with serous or 
haemorrhagic RPE detachment, sensory retinal detachment. 
 In a patient who complains of visual loss, metamorphopsia or 
scotoma of sudden onset, CNM should be suspected. Several clinical 
signs which suggest the presence of an underlying occult CNVM are: 
1. Overlying neurosensory RD 
2. Subretinal lipid 
3. Chorio retinal folds radiating from the PED. 
 
 Immediate FFA should be done to detect any treatable CNM. 
Careful stereoscopic slit lamp biomicroscopic examination using Hruby 
lens or 90 dioptre lens may increase the detection rate of CNM. 
       Histopathologically, a CNM appears as a neovascular sprout 
growing under or through the RPE via breaks in BM. The endothelial 
cells in the arborizing neovascular tuft lacks the barrier function of 
endothelial cells. So the new vessels leak fluid in the neurosensory, 
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subsensory and subretinal pigment epithelial layer of the retina. The 
fragile vessels are more prone to haemorrhage. Occasionally the blood 
may extend through all layers of the retina, breaking through into the 
vitreous cavity. Ultimately a fibro vascular scar results leading to 
disruption and death of the overlying retinal tissue and severe visual loss. 
CLASSIFICATION OF CNVM 
I . Based on location  
• Extrafoveal – CNV > 200 µm from center to FAZ 
• Juxtafoveal – CNV 1 – 199 µm from center to FAZ 
• Subfoveal – under the centre of FAZ 
II . Based on FFA  
• Classic CNVM  -  well defined early hyperfluorescence  with late 
leakage  
• Occult CNVM  –  fibrovascular PED 
                            -  late leakage from undetermined source  
• Predominantly classic CNVM - classic & occult with classic > 
50% 
• Minimally classic CNVM - classic & occult with classic CNVM < 
50%  
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Retinal Pigment Epithelial Detachments 
  Serous retinal pigment epithelial detachments (PED) appear 
clinically as sharply demarcated, dome shaped elevations of the 
RPE and overlying neurosensory retina. Neurosensory detachment 
may be due to an underlying occult CNVM.The causes of PED are  
 Fibrovascular tissue 
  Hemorrhage 
 Serous fluid 
 Coalescence of drusen  
Haemorrhagic RPE detachment 
Bleeding from CNM causes this clinical condition. Appears 
clinically as round, oval, sharply defined discrete elevation. Blood under 
RPE appears as dark green or red. Blood may dissect through the edges of 
detached RPE to subretinal space. Now it is seen as bright red color. 
Occasionally blood breaks through sensory retina and causes vitreous 
haemorrhage. 
RPE Tears 
Also referred to as RPE RIP. This is a known complication of 
PED. May happen spontaneously or follow laser photocoagulation. Gass 
suggested than an underlying NVM contributes to RPE tear formation. 
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When RPE tears, the free edge of the RPE retracts and rolls towards the 
mound of fibro vascular tissue. 
When RPE tear occur at the fovea, it leads to profound loss of 
vision. Tears occurs at the junction of attached and detached RPE. 
In a normal eye, fine basal laminar filaments anchor the RPE 
firmly to the inner collagenous zone of BM. 
In AMD, diffuse thickening of the inner aspect of BM seen 
clinically as confluent drusen appears to precede spontaneous serous RPE 
detachments. 
The clinical distinction between serous PED and confluent drusen 
is made on the basis of size and degree of elevation. Lesions larger than 
300 um are considered PED. 
Disciform Scar 
Both treated and untreated cases of choroidal neovascularization 
may progress to a fibrovascular scar. This involves the choroid, RPE and 
neurosensory retina. They present as yellow, white hyperpigmented areas. 
Disciform fibrovascular scar may continue to grow with 
neovascularization recurring at is edges, invading unaffected areas. 
Varying degrees of neurosensory fluid, haemorrhage and lipid may 
overlie the scar. 
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Disciform scar may masquerade as choroidal tumours when much 
pigment is seen. 
Histopathology reveals few surviving islands of photoreceptors 
cells. This may explain the better visual performance recorded than 
would be predicted. As a rule all disciform scar involves the fovea, 
resulting in severe visual loss. 
Break through vitreous haemorrhage 
Subretinal haemorrhage may break into the vitreous cavity. The 
exact mechanism of  its occurence is debatable. 
In most cases of exudative macular degeneration the peripheral 
retina remain unaffected. When bleeding occurs through the retina into 
the vitreous cavity, patients complain of severe and sudden loss of vision 
involving the peripheral field. 
Massive subretinal haemorrhage 
Rare complication of exudative AMD. Baba et al reported 19% of 
AMD patients with massive subretinal haemorrhage were on aspirin or 
warfarin.      
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FUNDUS FLUORESCEIN ANGIOGRAM 
FLUORESCENCE - property of certain molecules to emit light  of 
longer wavelength when stimulated by light of a shorter wave length.  
Normal patterns :    
1. Choroidal phase 
2. Arterial phase 
3. Arterio-Venous phase 
4. Venous phase 
5. Late phase      
Choroidal phase (pre arterial phase) 
 - Normal arm – retina time is 10-12 sec (young), 12-15 sec 
(old age) 
 - Dye reachs choroidal circulation through short posterior 
ciliary artery   
 - It has shorter course than CRA and enters 1-2sec earlier than 
retinal circulation 
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 - Early choroidal fluorescence is faint,patchy and irregular 
scattered throughout the posterior fundus interspersed with 
scattered islands of delayed filling- Choroidal flush 
 - When areas of choroidal filling and non filling are quite 
distinct the pattern is called Patchy choroidal filling 
  - Cilio retinal artery fills in this phase                  
Arterial phase 
 - Shows arterial filling and the continuation of choroidal  
  filling  
Arterio-Venous phase (capillary phase) 
- Complete filling of the arteries and capillaries 
- Early laminar flow in the veins in which the dye appears to 
line the venous wall leaving  an axial hypofluorescent strip  
Venous phase 
- Vascular flow is faster in the center of the vessels than on its 
side, so dye sticks to the walls of the vein which leads to 
Laminar flow 
- Early phase - complete arterial and capillary filling and more 
marked laminar venous flow 
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- Mid phase - almost complete venous filling and intensity of 
venous fluorescence is more than arteries 
- Late phase-veins are completely filled and arteries are 
starting to empty  
Late phase 
- Small amount of fluorescein entering the retinal circulation 
after having passed through the kidneys where most of the 
dye is eliminated 
- 10 mts after the injection the vessels of most normal patients 
are almost completely empty of fluorescein  
Fluorescein Angiographic features 
 Fundus fluorescein angiography is the single most useful 
diagnostic test in confirming the presence of an exudative lesion. It 
allows one to determine. 
1. The extent of lesion 
2. Definition of the lesion 
3. Location of the exudative lesion. 
 
 These above factors determine the prognostic importance and 
treatment implications. 
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 Exudative type of AMD - CNVM appear as a discrete, focal area 
of hyperfiuoresence, first observed before the dye has completely filled 
the retinal vessels, even during the stage of choroidal filling. 
Hyperfluorescence increases in both size and degree several minutes 
later. Fluorescein, may pool in subsensory retinal fluid. 
 A precise diagnosis and classification system of subretinal 
neovascularisation in AMD is needed to accurately evaluate the natural 
history and to select appropriate management 3. 
 On fluorescein angiography major types of new vessels are at 
present identifiable. 
1. CLASSIC  CNVM 
 Lacy pattern of hyperfluorescence in early phase and increase 
intensity in mid phase and Leaks in late phase obscuring the boundaries 
2. OCCULT CNVM 
 Speckled hyperflouresence with dye pooled in subretinal space in 
late phase or late leakage from undetermined source. 
 This group constitutes more than 50% of CNVMS associated with 
MD. This may be due to 
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1. Fluorescence and leakage are blocked by serous detachment 
2. RPE detachment 
3. Haemorraghic detachment 
4. Subretinal blood 
5. Turbid fluid and pigment. 
 
Visible SNV can be surrounded or can occur during the natural 
course, within an area of occult new vessels. 
Vascularised pigment epithelial detachments can contain either 
visible or more frequently subretinal neovascular membrane - which may 
be partially obscured by turbid or haemorrhagic fluid. 
Fluorescein angiography is of major value for the detection and 
precise location of the neovascular frond in relation to the centre of the 
foveal avascular zone. 
Other types of well defined CNVM 
Here CNVM is well defined but leakage is slow and subtle. 
Leakage may be limited because they may have enough endothelium to 
prevent leakage when blood flow is slow (Gass, 1985). 
In a few patients one may find diffuse ooze without cartwheel or 
lacy pattern. The geographic borders of well defined neovascular 
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membranes can be evaluated as they relate to the centre of the foveal 
avascular zone (the foveola). 
This allows to determine and classify subretinal new vessels into 4 
groups. 
1. Extrafoveal at more than 400 microns from the foveola 
2. Juxta foveal between 200 and 400 microns. 
3. Juxta foveolar between 5 and 200 microns. 
4. Retrofoveolar involving the centre. 
 
Subfoveal new vessels involve atleast 50% of the FAZ and will 
extend to all the FAZ or beyond. New vessels are either emerging directly 
under the fovea or growing from an extrafoveal position towards the 
fovea. 
Studies have demonstrated that 54% of visible vessels grow 
towards the fovea at the rate of 10-18 microns daily in a three-week 
period. 
More than 73% of extra foveal new vessels extend to a subfoveal 
location after one year. 
Among membranes invading all the FAZ three types can be 
considered. 
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1. Originating directly in the centre and limited to the FAZ. 
2. Larger and involving all the macular areas. 
3. Even more extensively to the entire posterior pole. 
 
Lesions of the retinal pigment epithelium detachment 
FFA shown rapid uniform fluorescence under the entire dome of 
the detachment. The dye does not leak beyond the margins of the 
detachment as the integrity of RPE and tight junctions between adjacent 
RPE/zonula occludens are intact still. However Bird hypothesis differ. He 
believes entry of the dye from choroid to sub RPE space is due to 
concentration gradient rather than due to fluid flow. Atypical features 
should not be missed. Clinical and angiographic features are : 
1. Notch sign, flattening, indentation of margin of detached RPE. 
2. Irregular or slowly filling RPE detachment 
3. Yellow subretinal exudate, haemorrhage at margins of RPE 
detachment. 
4. Radial chorioretinal folds surrounding RPE detachment. 
5.  Also serous detachment of sensory retina. 
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RPE Tears 
FFA reveals a zone of choroidal hyperfluorescence due to lack of 
RPE and a zone of blocked choroidal fluorescence due to doubling of 
RPE layer as a result of rolling of RPE on itself. 
Haemorrhagic RPE detachment 
 FFA shows a variety of pictures, may be slowly filling, partially 
blocked fluorescence. Some cases may show hot spot.  
INDOCYANINE GREEN ANGIOGRAPHY (ICG) 
 ICG is very much helpful in studying the choroidal circulation. The 
Occult CNVM is easily identified with ICG as a focal hyperfluorescent 
‘hot spot’, a plaque  or a combination of both. 
ICG IN CNVM 
1. Occult or poorly defined CNV  
2. Distinguishing serous from vascularised portion of fibrovascular 
PED 
3. CNV associated with overlying hemorrhage, pigment or exudate  
4. Recurrant CNV adjuvent to an old photocoagulation scar  
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OPTICAL COHERENCE TOMOGRAPHY 
Principle of OCT 
 Optical Ocoherence tomography is based on the principle of 
Michelson interferometry. Low coherence infra red light coupled to a 
fibre-optic travels to a beam – splitter and is directed through the ocular 
media to the retina and to the reference mirror respectively. Light passing 
through the eye is reflected by structures in different retinal layers. The 
distance between the beam splitter and the reference mirror is 
continuously varied. When the distance between the light source and the 
retinal tissue is equal to the distance between the light source and the 
reference mirror, the reflected light from the retinal tissue and reference 
mirror interacts to produce a interference pattern .The interference pattern 
is detected and then processed into a signal. 
 The signal is analogous to that obtained by a A-scan 
ultrasonography using light as a source rather than sound. A two-
dimensional image is built as the light source is moved across the retina. 
The image is in the form of a series of stacked and aligned A-scans, 
which produces a two-dimensional cross-sectional retinal image that 
resembles that of a histology. Digital processing aligns the A-scans to 
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correct for eye motion. Digital smoothing techniques are used to further 
improve the signal-to-noise ratio. 
NORMAL OCT SCAN 
 On a normal 10mm horizontal scan passing through the fovea, one 
can clearly demarcate two major landmarks, namely the optic disc and 
fovea. 
 The optic disc is seen towards the right of the tomogram can be 
easily identified by its contour. The central depression represents the 
optic head cup and the stalk continuing behind is the anterior part of the 
optic nerve. The fovea is seen towards the left of the tomogram and can 
be easily identified by characteristic thinning of the retinal layers. The 
vitreous anterior to the retina is non-reflective and is seen as a dark space. 
The interface between the non-reflective vitreous and backscattering 
retinal layers is the vitreoretinal interface. 
 Retinal morphology and the macular OCT imaging correlate well, 
with alignment of areas of high and low reflectively to specific retinal 
choroidal elements. 
 Resolution of retinal structures by OCT depends in the contrast in 
relative in reflectivity of adjacent structures. 
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 The nerve fiber layer and ganglion cell layers are reflective, and are 
seen as bright colors on the false color map. The nuclear layer appear 
hyporeflective, while the interconnecting plexiform layers and axonal 
layers are reflective hyper-reflective. Typically the photoreceptor appear 
slightly hyporeflective compared with the outer retinal layers. The retinal 
pigment epithelium – choriocapillaries complex is seen as hyper – 
reflective band. The retinal blood vessels within the neurosensory retina 
show backscatter and also cast a shadow behind. The choroid is also 
highly reflective, although it is frequently not well resolved because of 
light reflection by the overlying retinal pigment epithelium. 
OCT in CNVM  
1. Disease categorization – OCT gives an insight into the 
localization of pathology with changes occurring at the 
ultrastructural level that helps in categorizing the disease. 
 
2. Early occult CNVM – In patients with soft confluent drusen, 
occult CNVM can often be missed on FFA. 
 
3. Associated changes – OCT helps in depicting additional 
features like CME ,RPE rip, Neurosensory atrophy of retina. 
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4. To r/o the presence of underlying CNVM in patients with 
haemorrhagic PED. 
 
5. Response to treatment – OCT helps in monitoring response to 
photo coagulation, Transpupillary Thermo Therapy (TTT), 
Photo Dynamic Therapy (PDT). 
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MEDICAL TREATMENT 
Exudative type of AMD7  
1. Laser photocoagulation   
2. Anti VEGF agents 
- Pegaptanib Na (Macugen) 
- Bevacizumab (Avastin) 
- Ranibizumab (Lucentis)  
3. Photo Dynamic Therapy (Verteporfin) 
4 . Pupillary Thermotherapy 
5. Anecortave acetate  
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LASER PHOTO COAGULATION 
Historical Interest 
 
Zweng and associates used the Ruby laser to photocoagulate 20 
cases of AMD. They found no improvement in visual acuity in advanced 
cases but felt that laser photocoagulation in early cases might delay the 
progress of the disease. 
Watzke and Snyder employing Zenon photocoagulation 
demonstrated that it had definite value in early haemorrhagic disciform 
degeneration. 
Laser Treatment of well defined extrafoveal choroidal 
neovascular membranes 6 (CNVM ) 
The macular photocoagulation study (MPS) demonstrated that 
intense Argon blue-green laser photocoagulation treatment of extrafoveal 
CNVM significantly improved the visual prognosis as compared with the 
natural course of the disease. 
In this study eyes with a discrete extrafoveal CNVM and a baseline 
visual acuity of 20/100 or better were assigned to treatment. Intense 
Argon blue-green laser photocoagulation were applied to obliterate the 
CNVM. At 18 months following laser photocoagulation reduced the risk 
of severe visual loss from 69% in untreated eyes to 25% in treated eyes. 
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Disadvantages 
1. Three year follow up revealed that 47% of treated eyes versus 62% of 
untreated eyes progressed to severe visual loss. 
2. Recurrence of choroidal neovascularisation was responsible for most 
of the deterioration. 
3. Treatment appears to delay the onset of severe visual loss by 18 
months. 
4. Membranes within the FAZ and extrafoveal membranes extending 
into the FAZ were excluded. 
 Krypton red laser allows one to treat within the foveal avascular 
zone. There is less risk of damage to the fovea as a result of lack of 
uptake by the foveal xanthophyll. Also krypton laser spares the inner 
retina. 
 The National Eye Institute supported, Krypton Macular 
photocoagulation study and Foveal photocoagulation study are currently 
evaluating patients with NVM's within the FAZ. 
 In cases of poorly defined NVM, the patient is followed at frequent 
intervals with fluorescein angiography in the hope that the membrane 
will become well defined. 
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Principles of Photocoagulation 
Photocoagulation destroys the CNVM by heat. Laser light is 
absorbed by RPE, choroid and converted to heat which gets dissipated to 
adjacent tissues (Gass, 1981). 
RPE proliferation may also be a vital factor. Another theory 
proposes that laser treatment cause RPE to envelop CNVM and absorb 
the fluid overlying the CNVM (Miller, 1986). 
Laser may cause RPE proliferation as well as RPE derived 
inhibitors of neovascularisation. At time laser can cause total eradication 
of CNVM's.  
Preparation for treatment 
1. Patient should be informed that laser treatment will create a permanent 
blank area corresponding to the retina destroyed. 
2. Laser treatment may cause haemorrhage or increased neurosensory 
detachment. 
3. Laser treatment might actually stimulate new vessel growth in few 
cases. 
4. The ophthalmologist must emphasize to the patient that laser treatment 
is not a cure for macular degeneration. Laser treatment is designed to 
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obliterate the neovascular complex and reduce the risk of severe visual 
loss. 
Procedure 
1. FFA performed less than 72 hours before treatment. Ideally the 
angiogram should be less than 24 hours old. 
2. Projecting the angiogram on laser console top behind patients head is 
useful. 
3. A drawing of the choroidal NVM and its relationship to the FAZ 
made. 
4. The NVM perimeter, the FAZ and the key land marks around the 
membrane such as retinal vessels and subretinal blood are drawn. 
5. In MPS, retrobulbar anaesthesia was suggested to facilitate treatment. 
MPS  Photocoagulation Technique 
1. With the use of 200 um spot size and duration of atleast 0.2 second, 
a test burn is placed along the membrane perimeter. 
2. The foveal edge of the CNVM is treated next, with overlapping 
burn of 200 um of 0.2-0.5 seconds. The burns should be 
sufficiently intense to obliterate the CNVM. 
3. Then the rest of the membrane is outlined. 
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4. Finally the centre of CNM is treated and obliterated. 
5. MPS protocol requires the whole treated area should look 
uniformly intense white, extending 100 um beyond the 
angiographically visible CNM. 
6. Retinal vessels should be avoided. 
7. Choroidal haemorrhage is an occasional complication. 
8. While treating CNVM temporal to the optic DISC, MPS protocol 
says 1-2 clock hours of Papillo macular bundle be preserved. 
9. Treatment should never extend within 100-200 um from the disc. 
Post Treatment Care 
 
1. Ideally FFA should be taken immediately following treatment to 
check the adequacy of photocoagulation 
2. By comparing with pretreatment angiogram one can detect 
inadequacy of treatment. 
3. If need be additional treatment may be given. 
4. Usually first post operative examination is after 2 weeks. Later 
patients are examined at regular intervals of weeks - months. 
5. Each time FFA is done to detect any early CNVM recurrence. 
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6. Visual acuity stabilizes around 6 months in successfully treated 
eyes. 
7. Visual acuity may decline several years after treatment with 
enlargement of the treatment scar. 
Recurrences 
Despite adequate photocoagulation, treated eyes are at high risk for 
persistence of neovascularisation. The MPS reported that recurrent 
neovascularisation was present in 42% of treated eyes by 12 months and 
52% of eyes by 24 months. Eyes with recurrences progressed to severe 
visual loss. Retreatment of persistent or recurrent neovacularisation 
should be undertaken when the vessels are located outside the FAZ. 
In MPS, CNVM recurrence was associated with cigarette smoking. 
Complications of treatment 
1. Choroidal haemorrhage - to avoid, it guidelines are to avoid 
50 microns spot size and exposure time less than 0.2 
seconds. 
2. Localised field defects. 
3. Macular pucker - This is due to internal limiting membrane 
contraction. 
4. Occlusion of retinal vessels. 
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ANTI-VEGF AGENTS 
Stimulus for increased VEGF expression 
} Reduction in choriocapillary blood flow 
}  oxidative stress 
} Alteration in the Bruchs membrane 
}  Accumulation of the lipids 
MOA of VEGF 
 It  binds with flt1 and KDR receptors present in endothelial cells 
and increased  vascular permeability  and angiogenesis. Six types 
isoforms are VEGF 121,145,165,183, 189, 206  
MACUGEN (PEGAPTANIB)  - VISION TRIAL  
 Pegylated aptamer of VEGF that selectively block VEGF 165 , 
Pegylation increases half life and stability 
} Used in glaucoma patients 
} Dose-0.3mg 
} No benefit in occult CNV &  lesions more than 4DD. 
      FDA- approved in 2004 
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 BEVACIZUMAB (AVASTIN) 
Bevacizumab (Avastin, Genentech) is a full-length, humanized, 
murine  monclonal antibody directed against all the biologically active 
forms of vascular endothelial growth factor-A (VEGF). Bevacizumab, the 
first anti-VEGF drug to be approved by the Food and Drug 
Administration, was developed as an intravenous therapy for cancer 
patients because VEGF is one of the major angiogenic stimuli responsible 
for neovascularization in tumors. Anti-VEGF therapy has shown 
promising results in several forms of cancer, but the drug is currently 
approved only for the treatment of metastatic colorectal cancer. When 
used in cancer therapy, bevacizumab is infused at a dose of 5 mg/kg 
every two weeks until the patient dies or significant disease progression is 
observed. In clinical trials, the most common adverse event caused by be-
vacizumab was hypertension.  
Systemic Bevacizumab 
The role of VEGF in neovascular AMD has now been confirmed as 
the result of the Phase III clinical trial of the anti-VEGF drug pegaptanib 
sodium (Macugen, Eyetech). Pegaptanib sodium is now approved for the 
treatment of all neovascular AMD; however, the average pegaptanib-
treated patient still continues to lose vision while receiving therapy. 
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Another anti-VEGF drug known as ranibizumab (Lucentis, Genentech) 
was shown to improve visual acuity, angiographic and optical coherence 
tomography outcomes in open-label, uncontrolled Phase I/II studies. 
Genentech’s one-year, Phase III results confirm earlier studies in AMD 
patients. Patients with predominantly occult macular neovascularization 
treated with ranibizumab had an overall vision improvement and 
statistically significant better outcomes than the sham-injected controls. 
The disadvantages of systemic therapy, however, include systemic 
exposure to an antiangiogenic drug at therapeutic levels, resulting in a 
higher risk of systemic adverse events compared to intravenous injection. 
SANA STUDY 
In the spring of 2004, Systemic Avastin for Neovascular AMD 
(SANA) study at the Bascom Palmer Eye Institute. In this study systemic 
bevacizumab was offered as salvage therapy for patients who were not 
candidates for verteporfin photodynamic therapy or who refused PDT. 
Pegaptanib sodium was not yet commercially available. Unlike the regi-
mens used in cancer therapy, treating patients only two or three times 
followed by a period of close observation was proposed, with retreatment 
possible if the leakage from the neovascularization recurred. Since this 
article was published, a total of 18 patients have been followed for at least 
24 weeks, and the 24-week results confirm and improve upon the pre-
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liminary results observed at 12 weeks (submitted for publication). Of the 
18 patients, nine initially received three treatments, and 11 received only 
two treatments. The majority of patients did not require another treatment 
through 24 weeks. 
With improvement in visual acuity, OCT and angiographic 
outcomes, the systemic use of bevacizumab appeared to be both effective 
and durable. Moreover, the cost of intravenous bevacizumab therapy is 
comparable to the cost of pegaptanib therapy. The average drug cost for 
bevacizumab is $2,200 per infusion, and the cost for the 24 weeks of 
therapy is $4,400 for most patients, roughly equivalent to four intravitreal 
injections of pegaptanib over 24 weeks. 
Intravitreal Bevacizumab 
Bevacizumab was used as an intravitreal injection in humans in any 
of the early clinical studies. The preclinical data in primates suggested 
that intravitreal bevacizumab would be too large to penetrate the retina 
and result in any therapeutic effect, but bevacizumab was never tested in 
an animal model of macular neovascularization to see if this assumption 
was correct. Once we observed the dramatic results of systemic 
intravenous bevacizumab in patients with neovascular AMD, a much 
lower dose of bevacizumab injected into the eye could result in a similar 
benefit while reducing the risk of systemic adverse events. It has been 
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calculated that a dose of about 1 to 1.5 mg of bevacizumab would be ap-
proximately 400-fold less than the systemic dose of bevacizumab used in 
the SANA study. 
Another appealing feature of intravitreal bevacizumab is its low 
cost. Compared with the cost of pegaptanib sodium, an intravitreal dose 
of bevacizumab would be a bargain. While a dose of pegaptanib (0.3 mg) 
is approximately $1,000 or $3,300 per mg, the proposed 1-mg dose of 
bevacizumab would cost $5.50. Moreover, a dose of 1 to 1.25 mg could 
be conveniently injected using 0.04 ml to 0.05 ml of the commercially 
supplied bevacizumab, which is not known to contain preservatives or 
additives that may be toxic to the retina. At the Bascom Palmer Eye 
Institute, off-label intravitreal bevacizumab was offered to patients as a 
salvage treatment for those who continue to lose vision associated with 
neovascular lesions and worsening OCT profiles despite treatment with 
approved therapies. In the first report of a patient receiving intravitreal 
bevacizumab, improvement in angiographic and OCT outcomes after one 
injection were observed, nearly identical to the outcomes that observed 
following systemic bevacizumab and intravitreal ranibizumab. The 
patient’s vision remained stable over four weeks, and this patient has 
remained stable through six months and has not required another 
injection. 
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 INTRAVITREAL INJECTIONS–PROCEDURE GUIDELINES 
 Injection procedure guidelines include consideration of pre existing 
conditions such as active external infection, eyelid abnormalities, 
povidone iodine, lid scrubs, pre injection topical antibiotics, lid speculum, 
drape, gloves, and anaesthesia and post injection topical antibiotics.  
 In general the risk of endophthalmitis following intra vitreal 
injection is estimated to be approximately < 0.1%.  
Guidelines for intra vitreal injection 
1. Povidone iodine for ocular surface, eyelid and eye lashes 
2. Use of speculum and avoid contamination of the needle with eye lid 
margin 
3. Avoid extensive massage of the eye lids either pre or post injection 
4. Dilate pupil 
5. Adequate use of anaesthetic (topical drops/ sub conjunctival 
injection) 
6. Avoid prophylactic or post injection paracentesis 
7. IOP to be checked following injection 
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8. Dilated fundoscopic examination should be performed following 
injection to confirm central retinal artery perfusion and intra ocular 
location of the drug. 
Guidelines for follow up 
 
Patients should be followed up on the immediate day following 
intra vitreal injection. However patients should be instructed to contact 
ophthalmologist if there if increased ocular redness or discomfort or 
decreased vision compared to that present right after the injection 
procedure. 
 LUCENTIS (RANIBIZUMAB) 
It is a  recombinant humanized monoclonal antibody and binds to 
all isoforms of VEGF 
Dose- 0.5mg.It is used in minimally classical and occult CNV. 
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PHOTO DYNAMIC THERAPHY (PDT) 
Principle  
 Injection of photosensitizing drug followed by applying light of 
particular wave length to incite a photochemical reaction 
Mechanism 
 Oxygen free radicals, platelet activation  & thrombosis Æ 
occlusion of pathological vasculature  
Indication 
1. Predominantly classic CNV (TAP study) 
2. Occult / minimally classic CNV with recent disease 
progression (VIP study ) 
Procedure:      
} VERTEPORFIN -6mg/kg bw followed 5 min later by 
application of diode laser for 83 sec. 
} 5 to 6 session 3 monthly interval over a period of 2yr before 
disease stabilise.  
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ANECORTAVE ACETATE (RETANNE) 
} Derivative of cortisone with predominantly angiostatic effect. 
} Delivered behind the eye not within the eye . 
} No intra ocular complication . 
TRANS PUPILLARY THERMOTHERAPY (TTT) 
} Subfoveal CNV is slowly heated with diode laser to occlude cnv 
complex with single laser spot. 
} Less damage to overlying retina 
} Large Spot size 0.8 – 3 mm 
} Long exposure- 1 min 
} Power – 400-800 mW  
} Low irradiance 
} Wave length 810 nm 
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AIM OF THE STUDY 
1. To study the various FFA  patterns of exudative ARMD 
2. To study the role of OCT in diagnosing and monitoring the 
 treatment response 
3. To evaluate the change in visual acuity, macular thickness, 
 angiographic patterns following intravitreal injection of 
 bevacizumab. 
4. To assess the systemic risk factors for exudative ARMD. 
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MATERIALS AND METHODS 
This study was done in Retina clinic – Regional Institute of  
Ophthalmology and Government Ophthalmic Hospital, Chennai during 
the period of  June – 2007 to November – 2009. 
INCLUSION CRITERIA 
CNVM attributable to ARMD diagnosed by FFA and OCT with 
BCVA of less than 6 / 24. 
EXCLUSION CRITERIA 
1.  Non exudative ARMD 
2. High myopia 
3. Chronic uveitis 
4. Not associated with other ocular conditions like Diabetic 
 retinopathy, Hypertensive retinopathy 
5. Mature cataract 
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MATERIALS USED 
Vision in both eyes were tested using Snellen`s visual acuity chart. 
Other materials used were  
1) Direct ophthalmoscope 
2) Indirect ophthalmoscope 
3) Slit lamp examination with +90D lens 
4) Schiotz and Goldmann applanation tonometer 
5) Goldmann 3 mirror 
6) Topcon fundus camera 
7) Optical coherence tomography 
8) Fundus flourescein angiography 
9)  Blood pressure 
10) Urine-albumin sugar 
Complete ocular examination was done 
a. Best corrected visual acuity 
b. Intraocular pressure 
c. Anterior segment examination 
d. Visual fields 
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e. Fundus examination – pupil was dilated with 1% 
Tropicamide eye drops, fundus examination was done with 
Direct ophthalmoscope, Indirect ophthalmoscope, slit lamp 
with +90D lens and Goldmann 3 mirror. 
f. Fundus photograph was taken with Topcon fundus camera 
g. Fundus flourescein angiography was done in cases with 3ml 
of 20% Sodium flourescein injection IV in dorsal vein of 
hand with patient seated in front of fundus camera 
h. Optical Coherence Tomogram was done (OCT) for all 
patients. 
i. A commercially available bevacizumab (1.25mg/0.05ml)  
was prepared for each patient and placed in a tuberculin 
syringe  using aseptic techniques. After the eye had been 
prepared in a standard fashion using 5% povidone iodine and 
topical antibiotics, 1.25 mg (0.05 ml) of bevacizumab was 
injected intravitreally via the pars plana. After the injection, 
intraocular pressure and retinal artery perfusion were 
checked, and patients were instructed to administer topical 
antibiotics for 3 days. Patients were called 2 to 3 days after 
injection and were re examined within 1 week. 
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j. All the patients were asked for regular follow-up at 2weeks, 
4 weeks, 8weeks, 12weeks and 16weeks. At each visit 
patients were checked for intra-ocular pressure, BCVA,  
were checked and Fundus photograph, FFA, and OCT were 
recorded. 
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ANALYSIS AND DISCUSSION 
 I. AGE INCIDENCE                 
S.No Age – group (Years) No of patients Percentage 
1. 
2. 
3. 
4. 
5. 
50 – 54 
55 – 60 
61 – 70 
71 – 80 
81 – 90 
─ 
13 
21 
14 
2 
─ 
26 % 
42 % 
28 % 
4 % 
 
 
 In our study the predominant age group to be afflicted is the 61 – 
70 year range followed by 71- 80 year range followed by 55 – 60 year  
range, two patient between the age of 81 – 90 years were affected. This 
low incidence could be explained by the decreased life span of people in 
our country. None of our patients were below the age of 55 years. 
 This finding correlates with the study in western countries.     
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V. HIGH RISK FACTORS 
Total no of 
patients- 50 No of patients Percentage 
Hypertension 33 66 % 
Cardiac ailments 22 44 % 
Diabetes 5 10 % 
 
 
In our study 66% of the patients who were afflicted with AMD had 
hypertension. 
According to Stephen Ryan, conflicting results have appeared for 
the association between hypertension and AMD6. 
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44% of the patients in our study had non specific cardiac ailments. 
Most of the patients had non specific angina. So cardiologist opinion was 
obtained for all the cardiac patients before giving  avastin injection. 
According to Ryan a definite association seems to exist between 
AMD and cardiovascular disease6. 
This study also correlates  with the finding of Stephen Ryan. 
Five  patients in our series had diabetes mellitus. 
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X. MEDICAL MANAGEMENT 
Injection Bevacizumab ( Avastin ) 
A commercially available bevacizumab (1.25mg/0.05ml)  was 
prepared for each patient and placed in a tuberculin syringe  using aseptic 
techniques. After the eye had been prepared in a standard fashion using 
5% povidone iodine and topical antibiotics, 1.25 mg (0.05 ml) of 
bevacizumab was injected intravitreally via the parsplana 3mm from 
limbus in aphakia, 3.5mm from limbus in pseudophakia, 4mm from 
limbus in phakic patient in inferotemporal quadrent. After the injection, 
intraocular pressure and retinal artery perfusion were checked, and 
patients were instructed to administer topical antibiotics for 3 days. 
Patients were called 3 days after injection and were re examined within 1 
week. 
Patients received reinjections on a monthly basis until pigment 
epithelial detachment (PED) / or neovascularization resolved. 
MAIN OUTCOME MEASURES 
* Best corrected visual acuity (Snellen’s chart) 
* Macular thickness by OCT ( SPECTRAL)  
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* Changes in Fluorescein angiogram patterns in the form of 
reduction in size of the lesion and decrease in leakage. 
IMPROVEMENT IN VISUAL ACUITY 
Lines of 
improvement 
At  2 months At 4 months 
No change 6 4 
1 line 26 13 
2 lines 14 28 
¾ 2 lines 4 5 
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Most of the cases showed no change in visual acuity in 2 weeks, 
but about 52% cases with classic CNV showed 1 line improvement at the 
end of 2 months and 56% of cases showing 2lines improvement at the 
end of 4 months which correlates with Rich RM, Rosenfeld – et-all  
Retina ; 26:495-511. 8% patient showed no improvement at the end of 4 
months. 50%  of occult CNV showed more than 2 line improvement at 4 
months which is in par with Geitzenauer W – et-all, Klin Monatsbl 
Augenheilkd 2006; 223:822-7. 
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SUMMARY 
TO SUMUP IN THE STUDY 
 
1. 50  patients were studied during June – 2008 to November – 2009 
2. Of these 50 patients studied, 37 patients were above the age of 60 
years and the remaining 13 patients were below 60 years. 
3. The ratio of males to females in our study is 2.3 : 1. 
4. In our study 94% of the patients had bilateral involvement although 
both eyes were afflicted asymmetrically 
5. More than 60% of the patients were chronic smokers in our series. 
6. 66% of the patients had hypertension 
7 .     More than 44% of the patients in our study had non specific cardiac 
ailments. Most of the patients had angina, a few patients had 
previous history of myocardial infarction.  
8.     In our study most of the patients reported to the hospital very late in 
the course of the disease. 44% of the patients reported between 4 
months-6 months and 32% between 7-12 months.  
9. In our series 30% of the patients presented to us very late in the 
course of the disease, when the vision was less than 1/60. 41% of 
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patients presented when the VA was 2/60 – 4/60 and 29% between 
6/60 and 4/60. 
10.    In our study 68% of patients were with classical angiographic type 
with CNV, 24 % patients were occult type, 6 % of patients were 
PED and 2 % patients were disciform scar type.  
11.    About 46% of patients were with macular thickness between 250 - 
350µ and   22% of patients were with thickness more than 350µ and 
there were no patients with macular thickness less than 150µ. 
12.   All the patients were given 1.25mg of Bevacizumab intravitreally 
under aseptic precautions after explaining the procedure who then 
signed a consent form. Follow-up ranged from 2 to 16 weeks. All 
50 patients completed a 16-week follow-up visit. 
13.   During each follow-up, patients were checked for improvement in 
V/A, decrease in macular thickness and change in angiographic 
patterns. Fundus photographs were taken for documentation. 
14. 52% cases with classic CNV showed 1 line improvement in 
snellen’s chart at the end of 2 months and 56% of cases showing 2 
lines improvement at the end of 4 months. 
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15.   At the end of 2 months 24% of CNV showed leakage in the 
fluorescein angiography and 5% of leakage in 4 months 
16.   The qualitative assessment of the OCT showed marked reduction 
in subretinal fluid and cystic oedema 1month after injection. The 
earliest sign of reduction was the disappearance of SRF. About 
50% of Classic CNV and 40% of Occult CNV   showed reduction 
in macular thickness of 50µ at the end of 2 months, and 52% of 
both CNV types showed reduction of 100µ at the end of 4months. 
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CONCLUSION 
The following conclusions were arrived at from the above study. 
1. The incidence of AMD is high above the age of 60 years. This 
correlates with the Framingham Eye study. 
2. The sex incidence in our study reveal that males are more affected 
than females (ratio 2.3:1). This does not correlate with the existing 
studies. This may be explained by the fact that in our society most 
of the skilled jobs are being carried out by males. Since most of the 
female patients are housewives they are not aware of the 
deterioration in vision and are not reporting to the hospital. 
3. 94% have bilateral although asymetrical involvement of eyes. 
4. The Amsler Grid chart is one of the useful diagnostic test for 
follow up. 
5. 60% of the patients were chronic smokers in our series. In this 
regard there is scope for further detailed study in correlating the 
precipitating factor for AMD. 
6. Hypertension (66%) and cardiovascular disease (44%) are found to 
be the common systemic diseases associated with AMD. 
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7. FFA is very useful diagnostic tool in classifying the type of AMD 
and also to decide on the treatment modality. 
8.        OCT is useful in follow-up period. 
9. After inj Avastin 52% cases with classic CNV showed 1 line 
improvement in snellen’s chart at the end of 2 months and 56% of 
cases showing 2 lines improvement at the end of 4 months which 
correlates with Rich RM, Rosenfeld – et-all  Retina ; 26:495-511 
10. At the end of 4 weeks, 50% of both occult and classic types 
showed leakage and at the end of 4 months no cases of occult CNV 
showed leakage which supports the study of  Aiesenbrey et-all 
Graefes Arch Clin Exp Ophthalmol 2007; 245:941-8. 
11. About 50% of Classic CNV and 40% of Occult CNV   showed 
reduction in macular thickness of 50µ at the end of 2 months, and 
52% of both CNV types showed reduction of 100µ at the end of 
4months ,which correlates well with the study of Moschos MM – 
et-all Doc Ophthalmol 2007; 114:37-44. 
12.     Followup period of the patients ranged from 3 months to 8 months. 
Very few  patient was reported for regular followup. Reasons for 
this could be due to the old age patients were finding it difficult for 
a regular visit to hospital 
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In India ophthalmologists feel that AMD is an uncommon 
condition. By this study we prove that although its prevalence rate is low 
in India compared to western countries, Indians are not immune from 
developing AMD. 
In conclusion, I would like to add that there still exists grey areas 
in the understanding of AMD like its possible etiology, an effective 
medical treatment, as well as the effect of laser photo coagulation. The 
vast array of work done throughout the world regarding these aspects in 
AMD, amply testifies to the fact that the last word with regards to this 
disorder is yet to be written. Before concluding I would like to quote 
Benjamin Boyd who said 
“I cannot think of a more frustrating situation as clinical 
ophthalmologist than to see our patients deteriorate in sight and spirit as 
they develop AMD”. 
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PROFORMA 
 
Name                          Age          Sex           Occupation            
 
Op no      
 
 
Address 
 
Chief complaints: 
 
          . Defective vision 
          . Metamorphopsia 
          . Floaters 
 
Past history: 
 
          . Diabetes-                                 duration                 treatment 
          . Hypertension                          duration                 treatment 
          . Cardiovascular disease          duration                 treatment 
 
H/O smoking 
 
Sysetmic examination: 
 
            BP                         PR 
            RBS                      Urine-alb & sugar 
             
Cardiovascular system 
Ocular examination: 
                                         RE                                  LE 
Visual acuity  
Retinoscopy   
Tension    
Eye lids    
Conjunctiva          
Cornea                  
Anterior chamber  
Iris                        
Pupil                     
Lens                      
 
Fields 
Colour vision 
Amsler’s grid chart 
Fundus examination: 
     SLE +90D    
     Indirect ophthalmoscopy 
                                  
Fundus Fluorescein Angiography   
 
Optical coherence tomography       
 
Injection Bevacizumab (Avastin)    
 
Follow-up 
 
                 .Visual acuity 
                 .Tension 
                 . Amsler chart 
                 . Fundus by IDO 
                 . FFA 
                  
 
                            
  
 
KEY TO MASTER CHART 
 
 
VA  - Visual acuity 
FFA   - Fundus Fluorescein Angiography 
OCT  - Optical Coherance Tomogram 
HT      -  Hypertension 
DM      - Diabetes 
CVS   - Cardiovascular system 
ARMD – Age Related Macular Degeneration 
SMD   - Senile Macular Degeneration 
FAZ   - Foveal Avascular Zone 
RPE   - Retinal Pigment Epithelium 
BM  - Bruhs membrane 
CNVM – Choroidal neovascular membrane 
PED  – Pigment Epithelial Detachment 
GA  – Geographical Atrophy  
 
  
LIST OF SURGERIES PERFORMED 
 
S. 
No. Name Age
Se
x IP no. Diagnosis Surgeries 
1. Gopal 75 M 432578 RE-MC , LE- 
IMC 
RE – ECCE with 
PCIOL 
2. Devaki 56 F 421634 RE – IMC , 
LE - NC 
LE – ECCE with 
PCIOL 
3. Narasimman 63 M 431468 RE – MC , LE 
- MC 
RE – ECCE with 
PCIOL 
4. Kannammal 59 F 443290 BE - NC RE – ECCE with 
PCIOL 
5. Pongodi 65 F 479832 RE – MC , LE 
- IMC 
RE – ECCE with 
PCIOL 
6. Chellappan 81 M 456803 RE – Pseudo , 
LE - MC 
LE – ECCE with 
PCIOL 
7. Aathi 63 M 409876 RE – MC , LE 
- IMC 
RE – ECCE with 
PCIOL 
8. Palnisamy 61 M 460983 BE - NC LE – ECCE with 
PCIOL 
9. Kasthuri 58 F 456788 RE – PSEUD 
, LE - MC 
LE – ECCE with 
PCIOL 
10. Meenakshi 64 F 499887 RE – MC , LE 
-IMC 
RE – ECCE with 
PCIOL 
11. Chitra 35 F 794793 LE - 
Pterygium 
LE – Pterygium 
excision 
12. Nalliah 67 M 569797 RE- IMC, LE 
-Pseudo 
RE – SICS with 
PCIOL 
13. Kannan 62 M 637812 RE – 
Aphakia,LE - 
MC 
LE - ECCE 
14. Revathi 59 F 467901 BE - IMC RE – SICS with 
PCIOL 
S. 
No. Name Age
Se
x IP no. Diagnosis Surgeries 
15. Chinnaponnu 64 F 502167 RE – IMC , 
LE – NC 
LE – SICS with 
PCIOL 
16. Maran 70 M 50018 RE – Pseudo 
LE – IMC 
LE – SICS with 
PCIOL 
17. Vasanthakuma
ri 
60 F 617917 BE – NC RE – ECCE with 
PCIOL 
18. Rajasekar 58 M 483215 RE – IMC LE 
– MC 
LE – SICS with 
PCIOL 
19. Saroja 74 F 490427 RE – IMC LE 
- Pseudo 
RE – SICS with 
PCIOL 
20.  Dinesh 25 M 47873 LE – Rupture 
Globe 
LE- Corneal sclera 
tear suturing 
21.  Thippu 56 M 78965 RE – MC RE – SICS with 
PCIOL 
22.  Sabapathy 70 M 86989 RE  
Panophthalmit
is 
RE – Evisceration 
23. Gopal 65 M 776441 BE IMC LE SICS with 
PCIOL 
24 Chandra 65 F 886336 RE -MC  LE- 
Pseudo 
RE SICS with 
PCIOL 
25.  Murugan 50 M 85968 LE – Total 
RD 
LE – RD Surgery 
26. Kanniammal 60 F 684392 BE- IMC LE ECCE with 
PCIOL 
27. Maragatham 65 F 785391 RE –IMC LE  
- MC 
LE ECCE with 
PCIOL 
28. Elangovan 76 M 790160 RE- IMC LE- 
MC 
LE ECCE with PI 
29. Perumal 70 M 690437 RE- IMC LE -
MC 
LE ECCE with 
PCIOL 
S. 
No. Name Age
Se
x IP no. Diagnosis Surgeries 
30. Jayagopal 50 M 692899 BE -IMC RE ECCE with 
PCIOL 
31. Subramani 57 M 793525 RE- IMC LE -
MC 
LE ECCE with 
PCIOL 
32. Kaliammal 68 F 783728 BE- NC RE ECCE with 
PCIOL 
33. Annammal 60 F 674267 BE- MC LE ECCE with 
PCIOL 
34. Krishnaveni 50 F 725015 BE- IMC LE SICS  with 
PCIOL 
35. Muniyammal 65 F 816095 BE- IMC LE SICS with 
PCIOL 
36. Dhanalakshmi 46 F 785885 BE- IMC RE SICS with 
PCIOL 
37. Ramasamy 65 M 826095 BE- IMC RE SICS with 
PCIOL 
38. Vasantha 38 F 656005 RE -Pseudo 
LE -IMC 
LE ECCE with 
PCIOL 
39. Punitha 35 F 75940 RE - 
Pterygium 
RE 
Autograft/excision 
40. Ravi 64 M 634589 BE - IMC RE SICS with 
PCIOL 
41. Vellaiyan 55 M 847637 BE MC LE ECCE with 
PCIOL 
42. Dasappan 35 M 87720 LE Exposure 
keratitis 
LE medial 
tarsorrhaphy 
43. Etiappan 58 M 8912 LE-IMC LE – SICS 
withPCIOL 
44. Mariappan 52 M 792726 LE-IMC LE – SICS with 
PCIOL 
 
S. 
No. Name Age
Se
x IP no. Diagnosis Surgeries 
45. Shanthi 48 F 811986 BE- IMC RE SICS with 
PCIOL 
46. Varadhan 46 M 820826 RE-  CDC RE DCR 
47. Sumathy 54 F 762091 LE- CDC LE DCT 
48. Baskar 52 M 83940 RE-MC LE- 
IMC 
RE – SICS with 
PCIOL 
49. Venkatesh 56 M 78542 LE-IMC LE – SICS 
50. Lakshmi 72 F 84286 RE Ch dacryo 
cystitis 
RE -  DCT 
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 WET AMD WITH MACULAR THICKNESS OF 432µ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
PRE-INJECTION 
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CLASSIC CNVM 
 
 
Lacy pattern of hyperfluorescence  in early phase 
  Increase  intensity in mid phase. 
Leaks in late phase obscuring the boundaries 
 
 
 
 
  
 
Speckled hyperflouresence with dye pooled in subretinal space 
in late phase 
Vn FFA OCT Vn FFA OCT
1 RAJESHWARI 63 F 77321 ─ ─ + + + 5/60PH6/24 + 236 6/60NIP + 236 6/36NIP ─ 236
2 RAMACHANDRAN 68 M 44671 + ─ + ─ ─ 1/60NIP + 271 3/60NIP ─ 241 5/60PH6/24 ─ 227
3 SUNDARAM 65 M 25594 + ─ + ─ + 2/60PH4/60 + 386 3/60PH5/60 + 346 5/60PH6/60 ─ 268
4 NAGARAJAN 58 M 54092 + ─ + ─ + 6/60PH6/36 + 242 6/36NIP ─ 198 6/36PH6/24 ─ 138
5 WAHEDHA 57 F 35969 ─ ─ + ─ ─ 3/60PH4/60 + 312 3/60PH4/60 + 243 5/60PH6/60 + 146
6 VENKATESAN 76 M 48161 ─ ─ ─ ─ + HM + 344 2/60NIP ─ 305 3/60NIP ─ 265
7 ANNADURAI 56 M 44087 + ─ ─ ─ ─ 6/36PH6/24 + 178 6/24NIP ─ 178 6/24PH6/18 ─ 147
8 NAVANEETHA 70 F 40607 + ─ + ─ ─ 1/60PH2/60 + 227 3/60NIP + 227 6/60PH6/36 ─ 227
9 SATISHKUMAR 58 M 54004 + + ─ ─ ─ 2/60PH3/60 + 239 3/60PH4/60 ─ 186 5/60PH6/60 ─ 136
10 SENTHILRAJ 62 M 24122 + ─ ─ ─ + 2/60NIP + 386 5/60NIP + 241 6/60NIP ─ 174
11 JAYALAKSHMI 58 F 47368 ─ ─ + ─ ─ 5/60PH6/24 + 244 6/60PH6/24 ─ 226 6/60PH6/24 ─ 111
12 MEENAKSHI 67 F 45682 ─ ─ + ─ ─ 1/60PH3/60 + 365 3/60PH4/60 + 276 5/60PH6/60 ─ 234
13 MANIKUMAR 64 M 16099 + ─ ─ ─ + 4/60NIP + 228 6/60NIP + 228 6/36NIP ─ 228
14 PAULRAJ 57 M 58748 + + + + ─ 2/60PH4/60 + 298 5/60PH6/60 ─ 251 6/60PH6/36 ─ 193
15 KANMANI 65 F 43297 ─ ─ + ─ + 3/60NIP + 240 3/60NIP ─ 210 5/60NIP + 109
16 RADHABAI 55 F 48195 ─ ─ ─ ─ + 5/60PH6/24 + 396 6/60PH6/36 + 298 6/60PH6/36 ─ 148
17 PONNAMBALAM 68 M 33416 + ─ + ─ ─ 1/60NIP + 274 4/60NIP ─ 247 6/60NIP ─ 145
18 THOMAS 66 M 61817 + ─ ─ ─ ─ 4/60NIP + 250 6/60NIP + 220 6/60PH6/24 ─ 197
19 PERUMAL 60 M 85131 + ─ ─ ─ + 6/60NIP + 302 6/36NIP ─ 275 6/24NIP ─ 209
20 CHANDRA 78 F 32528 ─ ─ + ─ ─ 1/60PH2/60 + 371 3/60PH5/60 + 289 5/60PH6/60 + 145
21 KANNAPAN 62 M 31918 + ─ ─ ─ + 2/60PH4/60 + 198 3/60PH4/60 ─ 198 5/60NIP ─ 198
22 MUNUSAMY 74 M 44161 + ─ + + + 1/60NIP + 316 3/60PH4/60 ─ 288 6/60NIP ─ 148
23 SRINEVASAN 55 M 40709 + ─ ─ ─ + 6/60PH6/36 + 367 6/36NIP + 279 6/36PH6/24 + 235
24 LINGAM 71 M 61218 ─ + + + ─ 1/60PH3/60 + 228 2/60PH3/60 + 209 4/60PH6/60 ─ 155
25 PANGAJAM 64 F 31317 ─ ─ + ─ ─ 2/60PH4/60 + 325 2/60PH4/60 ─ 278 4/60PH6/60 ─ 123
26 SHANMUGAM 69 M 42188 + ─ ─ ─ + 2/60NIP + 229 3/60NIP + 229 5/60NIP ─ 174
27 MOHAN 56 M 38178 + + + + ─ 2/60PH3/60 + 371 4/60PH5/60 ─ 330 6/60PH6/36 ─ 157
28 SIVAKUMAR 61 M 54917 + ─ ─ ─ + 3/60PH4/60 + 230 4/60PH5/60 + 156 5/60PH6/60 ─ 156
29 VELAN 67 M 43237 + ─ + ─ ─ 1/60PH3/60 + 340 1/60PH3/60 ─ 310 4/60PH6/60 ─ 143
30 LOGANATHAN 59 M 56177 + ─ ─ ─ ─ 3/60NIP + 361 6/60NIP ─ 279 6/60NIP ─ 214
31 KAMATCHI 66 F 44749 ─ ─ + ─ + HM + 348 2/60NIP ─ 312 4/60PH5/60 ─ 167
32 SARADHA 55 F 42184 ─ ─ + ─ ─ 5/60PH6/24 + 350 6/60PH6/36 ─ 271 6/36NIP ─ 147
Sl.No Name Age Sex Op No.
Inj Avaastin Follow up
Smoking Alchol HT DM CVS
At 2 months At 4 months
Risk factors
 VN FFA OCT
33 KADHARBASHA 60 M 83711 + ─ + ─ ─ 1/60NIP + 236 3/60PH4/60 ─ 200 4/60PH5/60 ─ 165
34 NANTHAKUMAR 65 M 48175 + ─ ─ ─ + 2/60PH4/60 + 295 3/60PH4/60 ─ 165 5/60PH6/60 ─ 134
35 CHINNAMAL 63 F 33563 ─ ─ + ─ ─ 6/60PH6/36 + 287 6/36NIP + 203 6/36PH6/24 + 176
36 SIVAKUMAR 67 M 33368 ─ ─ + ─ + 1/60PH3/60 + 379 3/60PH5/60 ─ 297 5/60NIP ─ 167
37 POONGODI 56 F 42193 ─ ─ ─ ─ + 5/60PH6/24 + 235 6/60NIP ─ 205 6/36NIP ─ 173
38 VIJAYAKUMAR 73 M 24835 + ─ + ─ ─ HM + 270 2/60NIP + 270 5/60PH6/60 + 270
39 ARUMUGAM 62 M 33176 + + ─ ─ ─ 2/60PH3/60 + 383 3/60PH6/60 ─ 246 4/60PH6/60 ─ 190
40 KUMARASAMY 64 M 34197 + ─ + ─ + 2/60NIP + 275 2/60NIP + 234 4/60NIP ─ 210
41 THANDAPANI 70 M 33490 + ─ ─ ─ + 3/60PH4/60 + 238 6/60NIP ─ 238 6/60PH6/24 ─ 238
42 PRAKASH 57 M 33765 + ─ + ─ ─ 6/36PH6/24 + 311 6/60PH6/36 ─ 245 6/24NIP ─ 172
43 THIYAGARAJAN 82 M 33820 + + ─ ─ ─ 1/60PH2/60 + 317 3/60PH5/60 ─ 270 5/60PH6/60 ─ 136
44 RADHA  61 F 43591 ─ ─ + ─ + 6/60NIP + 328 6/36PH6/24 ─ 257 6/36PH6/24 ─ 217
45 RAJASEKAR 73 M 54172 + ─ + ─ + 3/60NIP + 289 5/60NIP + 169 6/36NIP ─ 129
46 ELLAPPAN 75 M 40027 ─ + ─ ─ ─ 2/60PH4/60 + 245 5/60PH6/60 + 211 6/60PH6/24 ─ 153
47 KUMARESAN 69 M 43996 + ─ + ─ ─ 1/60NIP + 255 3/60NIP ─ 255 5/60PH6/60 ─ 255
48 KALAVATHI 59 F 44178 ─ ─ + + + 5/60PH6/24 + 312 5/60PH6/24 + 247 6/60NIP ─ 216
49 MUTHU 66 M 32197 + ─ ─ ─ ─ 3/60NIP + 371 5/60PH6/60 ─ 331 6/60PH6/24 ─ 156
50 SRITHAR 55 M 45498 + ─ ─ ─ ─ 6/60NIP + 288 6/36NIP + 168 6/36PH6/24 ─ 127
